MedTrace Logo

Efficacy and Safety of ALGRX 4975 in Treatment of Postoperative Pain After Hernia Repair

NCT00146198 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2006-12-20

No results posted yet for this study

Summary

Hernia repair is one of the most common operations. Whilst there are few complications, pain may last for several weeks and extend the period of convalescence. ALGRX 4975 is an ultra-pure form of capsaicin, which is a pain medicine that has the potential for long-term pain relief following a single administration. This study will determine whether ALGRX 4975 can provide pain relief following hernia repair.

Conditions

  • Postoperative Pain

Interventions

DRUG

ALGRX 4975

Sponsors & Collaborators

  • AlgoRx Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Henrik Kehlet, MD PhD · Rigshospitalet, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2006-02-28

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00146198 on ClinicalTrials.gov